Narrative Review of Developing new Biomarkers for Decision Making in Advanced Testis Cancer

Lucia Nappi; Craig Nichols; Christian Kollmannsberger


Transl Androl Urol. 2021;10(10):4075-4084. 

In This Article


In conclusion, miR371 has the potential to increase the accuracy of detecting GCT and therefore to personalize the treatment of patients with this disease. There are immediate and clinically meaningful consequences if miR371 utility is clinically validated. This biomarker can minimize the rate of suboptimal treatments reducing long-term toxicity related to unnecessary treatments and therefore improving the quality of life and the life expectancy of the young GCT patients.